For patients weighing 50 kg (110 lb) or more: Give in two doses separated by at least 7 days. Give each dose as 500 mg for a total cumulative dose of 1000 mg of iron per course.
For patients weighing less than 50 kg (110 lb): Give in two doses separated by at least 7 days and give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1000 mg of Iron per course. Administer Ferijet intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 ml) per minute. When administered via infusion, dilute with sterile 0.9% Sodium Chloride injection, such that the concentration of the infusion is not less than 2 mg of iron per ml and administer over at least 15 minutes. When added to an infusion bag containing 0.9% Sodium Chloride Injection, at concentrations ranging from 2 mg to 4 mg of iron per ml, Ferijet solution is physically and stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/ml. Determination of the iron need

Hypersensitivity to Ferric Carboxymaltose injection or any of its components.

Observe signs and symptoms of hypersensitivity during and after this injection administration for at least 30 minutes and until clinically stable following completion
of each administration. Monitor patients closely for signs and symptoms of hypertension following each injection administration.

Nausea, hypertension, flushing, hypophosphatemia, dizziness etc.

Formal drug interaction studies have not been performed with Ferric carboxymaltose.

The use of Ferric carboxymaltose has not been studied in children and therefore is not recommended in children under 14 years.

Pregnancy: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect effects on human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

Breastfeeding: Clinical studies showed that transfer of iron from Ferric Carboxymaltose to human milk was negligible. Based on limited data on breastfeeding women it is unlikely that Ferric Carboxymaltose represents a risk to the breastfed child.
Fertility: There is no data on the effect of Ferric Carboxymaltose on human fertility. Fertility was unaffected following Ferric Carboxymaltose treatment in animal studies.

Ferijet 500 mg IV Injection: Each box contains one vial of 10 ml Ferric Carboxymaltose solution with one 100 ml normal saline (Sodisol), one infusion set, one alcohol pad, one first aid band, one disposable syringe (10 ml) and one hanger.